China SXT Pharmaceuticals, Inc. Announces Proposed Tender Offer for Common Shares … | News

TAIZHOU, China, Jan. 14, 2022 (GLOBE NEWSWIRE) — China SXT Pharmaceuticals, Inc. (“SXTC” or the “Company”), (NASDAQ: SXTC), a specialty pharmaceutical company focused on the research, development, manufacture, marketing and sale of traditional Chinese medicine (“TCMP”) parts, including advanced TCMPs (directly oral TCMP and TCMP after dipping), fine TCMPs, regular TCMPs and TCM counterpart supplements (“TCMHS”), today announced its intention to offer in an underwritten public offering its common stock and prefunded warrants to purchase common stock. The pre-funded warrants will be offered at the same price per share as the common shares, less the exercise price of $0.0001 per share of each pre-funded warrant. The Company intends to use the net proceeds of this offering for general corporate purposes, including, but not limited to, working capital and other business opportunities. The Offer is subject to market conditions, and there can be no assurance that the Offer will or will not be completed, or as to the actual size or terms of the Offer. The base offering is expected to be approximately $3.4 million and the underwriter will receive an over-allotment option to purchase an additional 15% of the number of common shares and/or pre-funded warrants sold for 45 days after closing.

Aegis Capital Corp. acts as the sole bookrunner for the offering.

This offering is made pursuant to an effective shelf registration statement on Form F-3 (No. 333-252664) previously filed with the United States Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on February 10, 2021. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement and accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th floor, New York, NY 10019, by email at [email protected] com, or by phone at (212) 813-1010. Before investing in this offering, interested parties should read the Prospectus Supplement and accompanying Prospectus in their entirety, as well as the other documents the Company has filed with the SEC and which are incorporated by reference into this prospectus supplement and accompanying prospectus, which provide further information about the Company and this offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of such state or territory.

About China SXT Pharmaceuticals, Inc.

Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company that focuses on the research, development, manufacturing, marketing and sales of parts of traditional Chinese medicine, which is a type of traditional Chinese. Medication that has been processed to be ready for use. For more information, please visit www.sxtchina.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding future plans, objectives, goals, strategies, events or performance, as well as underlying assumptions and other statements other than statements of historical fact. Where the Company uses words such as “may”, “will”, “intends”, “should”, “believes”, “expects”, “anticipates”, “projects”, “estimates” or similar expressions that do not relate solely to material, it makes forward-looking statements. Specifically, the Company’s statements regarding the closing of the proposed private placement are forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from the Company’s expectations described in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company’s objectives and strategies; the future business development of the Company; requesting and accepting products and services; changes in technology; the growth of the pharmaceutical market, in particular the Traditional Chinese Medicine Parts (“TCMP”) market, in China; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets served by the Company and the assumptions underlying or relating to any of the aforementioned risks and other risks contained in the reports filed by the Company with the Securities and Exchange Commission. For these and other reasons, investors are cautioned not to place undue reliance on any forward-looking statements contained in this press release. Other factors are discussed in the Company’s filings with the United States Securities and Exchange Commission, which may be viewed at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances occurring after the date hereof.

CONTACT:

Name: Feng Zhou

Email: [email protected]

Copyright 2022 GlobeNewswire, Inc.

Comments are closed.